Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 1;2(7):e24660.
doi: 10.4161/onci.24660. Epub 2013 Apr 30.

The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions

Shigeo Koido  1 , Sadamu Homma, Masato Okamoto, Yoshihisa Namiki, Kazuki Takakura, Kan Uchiyama, Mikio Kajihara, Toshifumi Ohkusa, Jianlin Gong, Hisao Tajiri
Affiliations

The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions

Shigeo Koido et al. Oncoimmunology. .

Abstract

The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of Toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to overcome the immunosuppressive effects of transforming growth factor β1.

Keywords: Toll-like receptor; cytotoxic T lymphocyte; dendritic cell; fusion cell; whole tumor cell.

PubMed Disclaimer

Figures

None
Figure 1. Effects of Toll-like receptor agonists on the immunogenicity of dendritic cell/tumor cell fusions. Dendritic cells (DCs) stimulated with a Toll-like receptor 2 (TLR2) agonist (PSK), a TLR4 agonist (OK-432), or both were fused with whole tumor cells by means of polyethylene glycol (PEG). DC/tumor cell fusions (FCs) were then maintained in the presence of PSK (PSK-FC), OK-432 (OK-FC) or both (OPK-FC). OPK-FCs elicit more robust cytotoxic T-lymphocyte (CTL) responses than PSK-FCs, OK-FCs, and unstimulated FCs.
See this image and copyright information in PMC

References

    1. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419–26. doi: 10.1038/nature06175. - DOI - PubMed
    1. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558–61. doi: 10.1038/nm0597-558. - DOI - PubMed
    1. Koido S, Hara E, Homma S, Namiki Y, Ohkusa T, Gong J, et al. Cancer vaccine by fusions of dendritic and cancer cells. Clin Dev Immunol. 2009;2009:657369. doi: 10.1155/2009/657369. - DOI - PMC - PubMed
    1. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675–80. doi: 10.1038/90609. - DOI - PubMed
    1. Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother. 2008;57:1271–8. doi: 10.1007/s00262-008-0459-8. - DOI - PMC - PubMed

LinkOut - more resources